FOR GENEVAX: FROM GENES TO TRANSNATIONAL VACCINES (Q2035463)

From EU Knowledge Graph
Revision as of 04:32, 20 March 2020 by DG Regio (talk | contribs) (‎Changed an Item)
Jump to navigation Jump to search
Project in Italy financed by DG Regio
Language Label Description Also known as
English
FOR GENEVAX: FROM GENES TO TRANSNATIONAL VACCINES
Project in Italy financed by DG Regio

    Statements

    country
    Italy
    0 references
    EU contribution
    186,460.21 Euro
    0 references
    budget
    372,920.43 Euro
    0 references
    co-financing rate
    50.0 percent
    0 references
    start time
    14 February 2017
    0 references
    expected end time
    13 October 2019
    0 references
    beneficiary name (string)
    EVVIVAX S.R.L.
    0 references
    ISTITUTO SUPERIORE DI SANITA'
    0 references
    beneficiary
    Q282303
    0 references
    Q275708
    0 references
    coordinate location

    41°53'35.95"N, 12°28'58.55"E
    0 references
    summary
    I VACCINI GENETICI HANNO MOLTEPLICI VANTAGGI POTENZIALI, TRA CUI IL TARGETING SPECIFICO, L'USO DI GENI MULTIPLI PER MIGLIORARE L'IMMUNITà, LA VELOCITà DI SINTESI E LA RIDUZIONE DEL RISCHIO RISPETTO AI VACCINI CONVENZIONALI. EVVIVAX Ê UNA NUOVA AZIENDA CH (Italian)
    0 references

    Identifiers

    Italian Unique Project Code
    F89J18000160007
    0 references
     
    Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q2035463&oldid=2483198"